Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection

References

• WeissmanMMBruceLLeafPJFlorioLHolzerCRobinsLNRegierDAAffective DisordersPsychiatric Disorders in America. The Epidemiologic Catchment Area StudyNew YorkThe Free Press19915380
   Google Scholar
• KesslerRThe National Comorbidity Survey of the United StatesInt Rev Psychiatry19946365376
   Google Scholar
• MerikangasKRAkiskalHSAngstJLifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replicationArch Gen Psychiatry2007564554355217485606
   PubMed Web of Science ®Google Scholar
• KleinmanLLowinAFloodEGandhiGEdgellERevickiDCosts of bipolar disorderPharmacoeconomics200321960162212807364
   PubMed Web of Science ®Google Scholar
• GreenbergPEKesslerRCBirnbaumHGThe economic burden of depression in the United States: how did it change between 1990 and 2000J Clin Psychiatry20031264121465147514728109
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellenceBipolar Disorder The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary CareNational Collaborating Centre for Mental HealthThe British Psychological Society and The Royal College of Psychiatrists2006
   Google Scholar
• SajatovicMMadhusoodananSFullerMAAulakhLKeatonDBRisperidone for bipolar disordersExpert Rev Neurother200535217718715853488
   PubMedGoogle Scholar
• VietaEGoikoleaJMCorbellaBRisperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open studyJ Clin Psychiatry200110621081882511816872
   PubMed Web of Science ®Google Scholar
• GuilleCSachsGSGhaemiSNA naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorderJ Clin Psychiatry2000961963864211030483
   PubMed Web of Science ®Google Scholar
• SmulevichABKhannaSEerdekensMKarcherKKramerMGrossmanFAcute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidolEur Neuropsychopharmacol20051151758415572276
   PubMed Web of Science ®Google Scholar
• KeckPEJrCalabreseJRMcIntyreRSAripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placeboJ Clin Psychiatry20071068101480149117960961
   PubMed Web of Science ®Google Scholar
• MuzinaDJMomahCEudiconeJMAripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled studyInt J Clin Pract2008562567968718373615
   PubMed Web of Science ®Google Scholar
• VietaESuppesTEggensIPerssonIPaulssonBBrecherMEfficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126)J Affect Disord20088109325126318579216
   PubMed Web of Science ®Google Scholar
• SuppesTVietaELiuSBrecherMPaulssonBMaintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127)Am J Psychiatry20094166447648819289454
   PubMed Web of Science ®Google Scholar
• DuffyAMilinRGrofPMaintenance treatment of adolescent bipolar disorder: open study of the effectiveness and tolerability of quetiapineBMC Psychiatry 20099419200370
   PubMed Web of Science ®Google Scholar
• CiprianiARendellJMGeddesJOlanzapine in long-term treatment for bipolar disorderCochrane Database Syst Rev20091CD00436719160237
   PubMed Web of Science ®Google Scholar
• GrofPSelecting effective long-term treatment for bipolar patients: monotherapy and combinationsJ Clin Psychiatry200364Suppl 5536112720485
   PubMed Web of Science ®Google Scholar
• SajatovicMBiswasKKilbourneAKFennHWillifordWBauerMSFactors associated with prospective long-term treatment adherence among individuals with bipolar disorderPsychiatr Serv2008759775375918586992
   PubMed Web of Science ®Google Scholar
• GianfrancescoFDRajagopalanKSajatovicMWangRHTreatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychoticsJ Clin Psychiatry2006267222223216566617
   PubMed Web of Science ®Google Scholar
• PatelMXTaylorMDavidASAntipsychotic long-acting injections: mind the gapBr J Psychiatry200911119552S1S4
   Web of Science ®Google Scholar
• CitromeLOlanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychoticInt J Clin Pract2009163114015018834452
   PubMed Web of Science ®Google Scholar
• KempDECananFGoldsteinBIMcIntyreRSLong-acting risperidone: a review of its role in the treatment of bipolar disorderAdv Ther2009626658859919562274
   PubMed Web of Science ®Google Scholar
• EreshefskyLMascarenasCAComparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamicsJ Clin Psychiatry200364Suppl 16182314680415
   PubMed Web of Science ®Google Scholar
• EerdekensMVanHIRemmerieBMannaertEPharmacokinetics and tolerability of long-acting risperidone in schizophreniaSchizophr Res2004917019110015246468
   PubMed Web of Science ®Google Scholar
• NesvagRHendsetMRefsumHTanumLSerum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medicationActa Psychiatr Scand200671141212616774657
   PubMed Web of Science ®Google Scholar
• NybergSErikssonBOxenstiernaGHalldinCFardeLSuggested Minimal Effective Dose of Risperidone Based on PET-Measured D2 and 5-HT2A Receptor Occupancy in Schizophrenic PatientsAm J Psychiatry199961156686987510360125
   PubMed Web of Science ®Google Scholar
• GefvertOErikssonBPerssonPPharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophreniaInt J Neuropsychopharmacol2005381273615710053
   PubMed Web of Science ®Google Scholar
• SurguladzeSAChuEMEvansAThe effect of long-acting risperidone on working memory in schizophrenia: a functional magnetic resonance imaging studyJ Clin Psychopharmacol20071227656057018004121
   PubMed Web of Science ®Google Scholar
• SurguladzeSAChuEMMarshallNEmotion processing in schizophrenia: fMRI study of patients treated with risperidone long-acting injections or conventional depot medicationJournal of Psychopharmacology2010in press
   Web of Science ®Google Scholar
• van BeijsterveldtLEGeertsRJLeysenJERegional brain distribution of risperidone and its active metabolite 9-hydroxyrisperidone in the ratPsychopharmacology (Berl)19942114153627531352
   PubMed Web of Science ®Google Scholar
• AravagiriMMarderSRBrain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to ratsPsychopharmacology (Berl)20022159442443111823895
   PubMed Web of Science ®Google Scholar
• KaneJMAgugliaEAltamuraACGuidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, ItalyEur Neuropsychopharmacol199828155669452941
   PubMed Web of Science ®Google Scholar
• RiedelMSchwarzMJStrassnigMRisperidone plasma levels, clinical response and side-effectsEur Arch Psychiatry Clin Neurosci20058255426126815565299
   PubMed Web of Science ®Google Scholar
• ThyssenARuschSHerbenVQuirozJMannaertERisperidone Long-Acting Injection: Pharmacokinetics Following Administration in Deltoid Versus Gluteal Muscle in Schizophrenic PatientsJ Clin Pharmacol2010123
   Web of Science ®Google Scholar
• MalempatiRNBondDJYathamLNDepot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patientsInt Clin Psychopharmacol20083232889418301123
   PubMed Web of Science ®Google Scholar
• HanCLeeMSPaeCUKoYHPatkarAAJungIKUsefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorderProgress in Neuro- Psychopharmacology and Biological Psychiatry2007311219122317532106
   PubMed Web of Science ®Google Scholar
• MohlAWestlyeKOpjordsmoenSLong-acting risperidone in stable patients with schizoaffective disorderJ Psychopharmacol2005919Suppl 5223116144783
   PubMed Web of Science ®Google Scholar
• CamachoANgBGalangueBFeifelDUse of risperidone long-acting injectable in a rural border community clinic in southern californiaPsychiatry (Edgmont)2008656434919727284
   PubMedGoogle Scholar
• NiazOSHaddadPMThirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient careActa Psychiatr Scand200771161364617559599
   PubMed Web of Science ®Google Scholar
• TaylorDPsychopharmacology and adverse effects of antipsychotic long-acting injections: a reviewBr J Psychiatry200911119552S13S19
   Web of Science ®Google Scholar
• BenabarreACastroPSanchez-MorenoJEfficacy and safety of long-acting injectable risperidone in maintenance phase of bipolar and schizoaffective disorder]Actas Esp Psiquiatr2009537314314719533426
   PubMed Web of Science ®Google Scholar
• YathamLNFalluABinderCEA 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorderActa Psychiatr Scand Suppl2007434505617688463
   PubMedGoogle Scholar
• SavasHAYumruMOzenMEUse of long-acting risperidone in the treatment of bipolar patientsJ Clin Psychopharmacol20061026553053116974200
   PubMed Web of Science ®Google Scholar
• VietaENietoEAutetAA long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidoneWorld J Biol Psychiatry20089321922418609430
   PubMed Web of Science ®Google Scholar
• MacfaddenWAlphsLHaskinsJTA randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequentlyBipolar Disord20091211882783919922552
   PubMed Web of Science ®Google Scholar
• JesteDVAlexopoulosGSBartelsSJConsensus statement on the upcoming crisis in geriatric mental health: research agenda for the next 2 decadesArch Gen Psychiatry1999956984885312884891
   PubMed Web of Science ®Google Scholar
• HirschfeldRMCalabreseJRWeissmanMMScreening for bipolar disorder in the communityJ Clin Psychiatry20031641535912590624
   PubMed Web of Science ®Google Scholar
• SinghDO’ConnorDWEfficacy and safety of risperidone long-acting injection in elderly people with schizophreniaClin Interv Aging2009435135519750235
   PubMed Web of Science ®Google Scholar
• KisslingWGluePMedoriRSimpsonSLong-term safety and efficacy of long-acting risperidone in elderly psychotic patientsHum Psychopharmacol20071222850551317902187
   PubMed Web of Science ®Google Scholar
• TaylorDMFischettiCSparshattAThomasABisharaDCorneliusVRisperidone long-acting injection: a prospective 3-year analysis of its use in clinical practiceJ Clin Psychiatry2009270219620019026261
   PubMed Web of Science ®Google Scholar
• SajatovicMJenkinsJHCassidyKAMuzinaDJMedication treatment perceptions, concerns and expectations among depressed individuals with Type I Bipolar DisorderJ Affect Disord20096115336036618996600
   PubMed Web of Science ®Google Scholar
• BurnsTKnowledge about antipsychotic long-acting injections: bridging that gapBr J Psychiatry200911119552S5S6
   Web of Science ®Google Scholar